Editions:  Austria · Denmark · France · Germany · Italy · Norway · Spain · Sweden · Switzerland

Bayer bids $2.4bn for Norway pharma firm

Share this article

Bayer bids $2.4bn for Norway pharma firm
Xofigo, Algeta's leading cancer treatment - Algeta
11:00 CET+01:00
German pharmaceutical group Bayer has made a bid for its Norwegian partner and competitor Algeta, specialised in cancer treatments, for 1.8 billion euro ($2.4 billion), the Nordic company said on Tuesday.
In a statement to the Oslo Stock Exchange responding to recent media reports, Algeta said that Bayer had offered 336 kroner (40.7 euro, $55.2) per share.
The company added that the acquisition price quoted in the media (306  kroner) was lower than the actual offer from the German group.
The bid was 27 percent higher than the last closing price of Algeta (264,60 kroner).
Algeta is specialised in radiotherapy treatments that use radium 223 and thorium 227 to destroy cancer cells while causing minimal damage to surrounding tissue.
The company's leading product Xofigo -- a treatment for prostate cancer -- was approved for use in the US in May and is distributed in cooperation with Bayer.
Get notified about breaking news on The Local

Share this article

From our sponsors

Change the world with a master’s degree from Sweden’s Linköping University

Master’s students at world-leading Linköping University (LiU) aren’t there simply to study. They solve real-world problems alongside experts in fields that can create a better tomorrow. Do you have what it takes to join them?